Adicet Bio (ACET) Other Non-Current Liabilities (2017 - 2025)
Adicet Bio (ACET) posted quarterly Other Non-Current Liabilities of $62000.0 for Q4 2025, down 46.55% year-over-year from $116000.0 in Q4 2024, and down 50.4% quarter-over-quarter from $125000.0 in Q3 2025.
Adicet Bio (ACET) Other Non-Current Liabilities (2017 - 2025) Analysis & Trends
Adicet Bio's Other Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $62000.0 for Q4 2025.
- In Q4 2025, Other Non-Current Liabilities fell 46.55% year-over-year to $62000.0; the TTM figure through Dec 2025 stood at $62000.0 (down 46.55% YoY), while the FY2025 annual figure was $62000.0, down 46.55% from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $62000.0, down from $125000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $600000.0 in Q1 2021, with the low at $62000.0 in Q4 2025.
- The 5-year median for Other Non-Current Liabilities is $116000.0 (2021), against an average of $141736.8.
- Peak annual rise in Other Non-Current Liabilities reached 2400.0% in 2021, while the deepest fall reached 88.27% in 2021.
- Adicet Bio's Other Non-Current Liabilities stood at $115000.0 in 2021, then declined by 0.87% to $114000.0 in 2022, then advanced by 14.04% to $130000.0 in 2023, then fell by 10.77% to $116000.0 in 2024, then plunged by 46.55% to $62000.0 in 2025.
- Business Quant data shows ACET's Other Non-Current Liabilities at $62000.0 in Q4 2025, $125000.0 in Q3 2025, and $116000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Adicet Bio | 98.21 Mn | -19.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 62,000.00 |
| Sep 30, 2025 | 125,000.00 |
| Jun 30, 2025 | 116,000.00 |
| Mar 31, 2025 | 116,000.00 |
| Dec 31, 2024 | 116,000.00 |
| Sep 30, 2024 | 116,000.00 |
| Jun 30, 2024 | 116,000.00 |
| Mar 31, 2024 | 116,000.00 |
| Dec 31, 2023 | 130,000.00 |
| Sep 30, 2023 | 143,000.00 |
| Jun 30, 2023 | 130,000.00 |
| Mar 31, 2023 | 116,000.00 |
| Dec 31, 2022 | 114,000.00 |
| Sep 30, 2022 | 116,000.00 |
| Jun 30, 2022 | 115,000.00 |
| Mar 31, 2022 | 115,000.00 |
| Dec 31, 2021 | 115,000.00 |
| Sep 30, 2021 | 116,000.00 |
| Mar 31, 2021 | 600,000.00 |
| Dec 31, 2020 | 980,000.00 |